February 08 2022
The NRG-CC008/SOROCk trial builds on clinical and translational research that suggests most ovarian cancers begin in the distal fallopian tube. Preliminary data from the SU2C WISP trial has shown that leaving ovaries in place, but removing the tubes helps younger, high-risk (BRCA mutation) women retain hormonal function. However, the SU2C WISP trial was not designed to determine whether or not removing just the tubes – instead of both tubes and ovaries – prevents ovarian cancer. What is needed is a decisive clinical trial.
Along these lines, the SOROCk trial is an international clinical trial, designed to convert this preliminary data into clinical action. This study aims to define the role of tube versus ovary removal on cancer incidence. It is a non-randomized trial where BRCA1 carriers will self-select their preferred surgical intervention. This trial will determine if bilateral salpingectomy is non-inferior to bilateral salpingo-oophorectomy to reduce the risk of ovarian cancer.
“This is a critically important study as we need a properly powered trial to address the impact of bilateral salpingectomy on ovarian cancer incidence,” comments Warner K. Huh, MD, of the UAB Department of Obstetrics/Gynecology and the O’Neal Comprehensive Cancer Center and Co-Principal Investigator of the NRG-CC008 trial.
As of this writing, 110 patients have been enrolled onto this trial.
View the NRG Oncology SOROCk Webpage